secwatch.observer — SEC 8-K summary
======================================

Issuer:     SeaStar Medical Holding Corp (ICU)
CIK:        0001831868
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059518
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SeaStar Medical Q1 net loss $12.7M, cash rises to $5M; Quelimmune launch imminent
--------------------------------------------------------------------------------

- Net loss $12.7M ($0.19 per share) vs $7.1M ($0.54) in Q1 2023; no revenue recorded.
- Cash and cash equivalents $5.0M as of March 31, 2024, up from $176K at Dec 31, 2023.
- Quelimmune Pediatric received FDA approval in Feb 2024; initial sales expected in coming weeks at five children's hospitals.
- NEUTRALIZE-AKI adult trial enrolled 31 subjects at eight sites; regulatory approval expected H2 2025.
- January 2024 $9M at-the-market offering and appointment of David A. Green as CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831868/000095017024059518/0000950170-24-059518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831868/000095017024059518/icu-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer